Effects of (R)-9-(2-phosphonylmethoxypropyl)adenine monotherapy on chronic SIV infection in macaques
(R)-9-(2-Phosphonylmethoxypropyl)adenine (PMPA) acts as a reverse transcriptase inhibitor of retroviruses and has been shown to be effective against acute simian immunodeficiency virus (SIV) infection in macaques. To study its efficacy at different stages of infection, we tested PMPA in cynomolgus m...
Gespeichert in:
| Veröffentlicht in: | AIDS research and human retroviruses 1997-05, Vol.13 (8), p.707-712 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 712 |
|---|---|
| container_issue | 8 |
| container_start_page | 707 |
| container_title | AIDS research and human retroviruses |
| container_volume | 13 |
| creator | TSAI, C.-C FOLLIS, K. E BECK, T. W SABO, A BISCHOFBERGER, N DAILEY, P. J |
| description | (R)-9-(2-Phosphonylmethoxypropyl)adenine (PMPA) acts as a reverse transcriptase inhibitor of retroviruses and has been shown to be effective against acute simian immunodeficiency virus (SIV) infection in macaques. To study its efficacy at different stages of infection, we tested PMPA in cynomolgus macaques (Macaca fascicularis) that had been chronically infected with SIVMne for at least 19 weeks before treatment was begun. PMPA was administered subcutaneously in a single daily dose of either 30 or 75 mg/kg body weight for 28 days. Within < or = 2 weeks of treatment, PMPA in both dosing regimens reduced SIV levels by >99% in the plasma or peripheral blood mononuclear cells; in some macaques SIV levels were reduced to below the lower quantitation limit. At a dose of 30 mg/kg/day PMPA was well tolerated, causing no side effects while increasing the mean CD4+ cell counts in animals that received this dose. Thus PMPA seems to be a promising agent for use against retroviral infections. |
| doi_str_mv | 10.1089/aid.1997.13.707 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_15993395</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>15993395</sourcerecordid><originalsourceid>FETCH-LOGICAL-c352t-e1de898abc4fd0e5f6fccb87fe796602098768b9ce016064e4dac6e84f1b8903</originalsourceid><addsrcrecordid>eNo9kMtLxDAQxoMouj7OnoQeRPTQNY82zRxF1gcIgorXkKYTNtImtemC_e_t4uJhGJjvm2-GHyHnjC4ZVXBrfLNkANWSiWVFqz2yYCBYrgpa7pMFVQpyzjkckeOUviilwHl5SA6BScUFLEizcg7tmLLosuu3mxzya57365jmClPb4biOP1M_xH5qb0yDwQfMuhjiuMbB9FMWQ2bXQwzeZu_Pn5kP2zg_T33IOmPN9wbTKTlwpk14tusn5ONh9XH_lL-8Pj7f373kVpR8zJE1qECZ2hauoVg66aytVeWwAikpp6AqqWqwSJmkssCiMVaiKhyrFVBxQq7-Yud3t2dH3flksW1NwLhJmpUAQkA5G2__jHaIKQ3odD_4zgyTZlRvseoZq95i1UzoGeu8cbGL3tQdNv_-HcdZv9zpJlnTusEE69O_jUuoVAniF01QgUk</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>15993395</pqid></control><display><type>article</type><title>Effects of (R)-9-(2-phosphonylmethoxypropyl)adenine monotherapy on chronic SIV infection in macaques</title><source>Mary Ann Liebert Online Subscription</source><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>TSAI, C.-C ; FOLLIS, K. E ; BECK, T. W ; SABO, A ; BISCHOFBERGER, N ; DAILEY, P. J</creator><creatorcontrib>TSAI, C.-C ; FOLLIS, K. E ; BECK, T. W ; SABO, A ; BISCHOFBERGER, N ; DAILEY, P. J</creatorcontrib><description>(R)-9-(2-Phosphonylmethoxypropyl)adenine (PMPA) acts as a reverse transcriptase inhibitor of retroviruses and has been shown to be effective against acute simian immunodeficiency virus (SIV) infection in macaques. To study its efficacy at different stages of infection, we tested PMPA in cynomolgus macaques (Macaca fascicularis) that had been chronically infected with SIVMne for at least 19 weeks before treatment was begun. PMPA was administered subcutaneously in a single daily dose of either 30 or 75 mg/kg body weight for 28 days. Within < or = 2 weeks of treatment, PMPA in both dosing regimens reduced SIV levels by >99% in the plasma or peripheral blood mononuclear cells; in some macaques SIV levels were reduced to below the lower quantitation limit. At a dose of 30 mg/kg/day PMPA was well tolerated, causing no side effects while increasing the mean CD4+ cell counts in animals that received this dose. Thus PMPA seems to be a promising agent for use against retroviral infections.</description><identifier>ISSN: 0889-2229</identifier><identifier>EISSN: 1931-8405</identifier><identifier>DOI: 10.1089/aid.1997.13.707</identifier><identifier>PMID: 9168239</identifier><identifier>CODEN: ARHRE7</identifier><language>eng</language><publisher>Larchmont, NY: Liebert</publisher><subject>Adenine - analogs & derivatives ; Adenine - therapeutic use ; Adenine - toxicity ; Animals ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Antiviral agents ; Antiviral Agents - pharmacokinetics ; Antiviral Agents - therapeutic use ; Biological and medical sciences ; CD4-Positive T-Lymphocytes - drug effects ; Drug Evaluation ; Lymphocyte Count - drug effects ; Lymphocyte Subsets - cytology ; Lymphoid Tissue - pathology ; Lymphoid Tissue - virology ; Macaca fascicularis ; Macaca fascicularis - virology ; Medical sciences ; Organophosphonates ; Organophosphorus Compounds - therapeutic use ; Organophosphorus Compounds - toxicity ; Pharmacology. Drug treatments ; Retroviridae Infections - blood ; Retroviridae Infections - drug therapy ; simian immunodeficiency virus ; Simian Immunodeficiency Virus - drug effects ; Simian Immunodeficiency Virus - genetics ; Simian Immunodeficiency Virus - growth & development ; Tenofovir</subject><ispartof>AIDS research and human retroviruses, 1997-05, Vol.13 (8), p.707-712</ispartof><rights>1997 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c352t-e1de898abc4fd0e5f6fccb87fe796602098768b9ce016064e4dac6e84f1b8903</citedby><cites>FETCH-LOGICAL-c352t-e1de898abc4fd0e5f6fccb87fe796602098768b9ce016064e4dac6e84f1b8903</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,3042,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2697859$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9168239$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>TSAI, C.-C</creatorcontrib><creatorcontrib>FOLLIS, K. E</creatorcontrib><creatorcontrib>BECK, T. W</creatorcontrib><creatorcontrib>SABO, A</creatorcontrib><creatorcontrib>BISCHOFBERGER, N</creatorcontrib><creatorcontrib>DAILEY, P. J</creatorcontrib><title>Effects of (R)-9-(2-phosphonylmethoxypropyl)adenine monotherapy on chronic SIV infection in macaques</title><title>AIDS research and human retroviruses</title><addtitle>AIDS Res Hum Retroviruses</addtitle><description>(R)-9-(2-Phosphonylmethoxypropyl)adenine (PMPA) acts as a reverse transcriptase inhibitor of retroviruses and has been shown to be effective against acute simian immunodeficiency virus (SIV) infection in macaques. To study its efficacy at different stages of infection, we tested PMPA in cynomolgus macaques (Macaca fascicularis) that had been chronically infected with SIVMne for at least 19 weeks before treatment was begun. PMPA was administered subcutaneously in a single daily dose of either 30 or 75 mg/kg body weight for 28 days. Within < or = 2 weeks of treatment, PMPA in both dosing regimens reduced SIV levels by >99% in the plasma or peripheral blood mononuclear cells; in some macaques SIV levels were reduced to below the lower quantitation limit. At a dose of 30 mg/kg/day PMPA was well tolerated, causing no side effects while increasing the mean CD4+ cell counts in animals that received this dose. Thus PMPA seems to be a promising agent for use against retroviral infections.</description><subject>Adenine - analogs & derivatives</subject><subject>Adenine - therapeutic use</subject><subject>Adenine - toxicity</subject><subject>Animals</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Antiviral agents</subject><subject>Antiviral Agents - pharmacokinetics</subject><subject>Antiviral Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>CD4-Positive T-Lymphocytes - drug effects</subject><subject>Drug Evaluation</subject><subject>Lymphocyte Count - drug effects</subject><subject>Lymphocyte Subsets - cytology</subject><subject>Lymphoid Tissue - pathology</subject><subject>Lymphoid Tissue - virology</subject><subject>Macaca fascicularis</subject><subject>Macaca fascicularis - virology</subject><subject>Medical sciences</subject><subject>Organophosphonates</subject><subject>Organophosphorus Compounds - therapeutic use</subject><subject>Organophosphorus Compounds - toxicity</subject><subject>Pharmacology. Drug treatments</subject><subject>Retroviridae Infections - blood</subject><subject>Retroviridae Infections - drug therapy</subject><subject>simian immunodeficiency virus</subject><subject>Simian Immunodeficiency Virus - drug effects</subject><subject>Simian Immunodeficiency Virus - genetics</subject><subject>Simian Immunodeficiency Virus - growth & development</subject><subject>Tenofovir</subject><issn>0889-2229</issn><issn>1931-8405</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1997</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kMtLxDAQxoMouj7OnoQeRPTQNY82zRxF1gcIgorXkKYTNtImtemC_e_t4uJhGJjvm2-GHyHnjC4ZVXBrfLNkANWSiWVFqz2yYCBYrgpa7pMFVQpyzjkckeOUviilwHl5SA6BScUFLEizcg7tmLLosuu3mxzya57365jmClPb4biOP1M_xH5qb0yDwQfMuhjiuMbB9FMWQ2bXQwzeZu_Pn5kP2zg_T33IOmPN9wbTKTlwpk14tusn5ONh9XH_lL-8Pj7f373kVpR8zJE1qECZ2hauoVg66aytVeWwAikpp6AqqWqwSJmkssCiMVaiKhyrFVBxQq7-Yud3t2dH3flksW1NwLhJmpUAQkA5G2__jHaIKQ3odD_4zgyTZlRvseoZq95i1UzoGeu8cbGL3tQdNv_-HcdZv9zpJlnTusEE69O_jUuoVAniF01QgUk</recordid><startdate>19970520</startdate><enddate>19970520</enddate><creator>TSAI, C.-C</creator><creator>FOLLIS, K. E</creator><creator>BECK, T. W</creator><creator>SABO, A</creator><creator>BISCHOFBERGER, N</creator><creator>DAILEY, P. J</creator><general>Liebert</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7U9</scope><scope>H94</scope></search><sort><creationdate>19970520</creationdate><title>Effects of (R)-9-(2-phosphonylmethoxypropyl)adenine monotherapy on chronic SIV infection in macaques</title><author>TSAI, C.-C ; FOLLIS, K. E ; BECK, T. W ; SABO, A ; BISCHOFBERGER, N ; DAILEY, P. J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c352t-e1de898abc4fd0e5f6fccb87fe796602098768b9ce016064e4dac6e84f1b8903</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1997</creationdate><topic>Adenine - analogs & derivatives</topic><topic>Adenine - therapeutic use</topic><topic>Adenine - toxicity</topic><topic>Animals</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Antiviral agents</topic><topic>Antiviral Agents - pharmacokinetics</topic><topic>Antiviral Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>CD4-Positive T-Lymphocytes - drug effects</topic><topic>Drug Evaluation</topic><topic>Lymphocyte Count - drug effects</topic><topic>Lymphocyte Subsets - cytology</topic><topic>Lymphoid Tissue - pathology</topic><topic>Lymphoid Tissue - virology</topic><topic>Macaca fascicularis</topic><topic>Macaca fascicularis - virology</topic><topic>Medical sciences</topic><topic>Organophosphonates</topic><topic>Organophosphorus Compounds - therapeutic use</topic><topic>Organophosphorus Compounds - toxicity</topic><topic>Pharmacology. Drug treatments</topic><topic>Retroviridae Infections - blood</topic><topic>Retroviridae Infections - drug therapy</topic><topic>simian immunodeficiency virus</topic><topic>Simian Immunodeficiency Virus - drug effects</topic><topic>Simian Immunodeficiency Virus - genetics</topic><topic>Simian Immunodeficiency Virus - growth & development</topic><topic>Tenofovir</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>TSAI, C.-C</creatorcontrib><creatorcontrib>FOLLIS, K. E</creatorcontrib><creatorcontrib>BECK, T. W</creatorcontrib><creatorcontrib>SABO, A</creatorcontrib><creatorcontrib>BISCHOFBERGER, N</creatorcontrib><creatorcontrib>DAILEY, P. J</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>AIDS research and human retroviruses</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>TSAI, C.-C</au><au>FOLLIS, K. E</au><au>BECK, T. W</au><au>SABO, A</au><au>BISCHOFBERGER, N</au><au>DAILEY, P. J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effects of (R)-9-(2-phosphonylmethoxypropyl)adenine monotherapy on chronic SIV infection in macaques</atitle><jtitle>AIDS research and human retroviruses</jtitle><addtitle>AIDS Res Hum Retroviruses</addtitle><date>1997-05-20</date><risdate>1997</risdate><volume>13</volume><issue>8</issue><spage>707</spage><epage>712</epage><pages>707-712</pages><issn>0889-2229</issn><eissn>1931-8405</eissn><coden>ARHRE7</coden><abstract>(R)-9-(2-Phosphonylmethoxypropyl)adenine (PMPA) acts as a reverse transcriptase inhibitor of retroviruses and has been shown to be effective against acute simian immunodeficiency virus (SIV) infection in macaques. To study its efficacy at different stages of infection, we tested PMPA in cynomolgus macaques (Macaca fascicularis) that had been chronically infected with SIVMne for at least 19 weeks before treatment was begun. PMPA was administered subcutaneously in a single daily dose of either 30 or 75 mg/kg body weight for 28 days. Within < or = 2 weeks of treatment, PMPA in both dosing regimens reduced SIV levels by >99% in the plasma or peripheral blood mononuclear cells; in some macaques SIV levels were reduced to below the lower quantitation limit. At a dose of 30 mg/kg/day PMPA was well tolerated, causing no side effects while increasing the mean CD4+ cell counts in animals that received this dose. Thus PMPA seems to be a promising agent for use against retroviral infections.</abstract><cop>Larchmont, NY</cop><pub>Liebert</pub><pmid>9168239</pmid><doi>10.1089/aid.1997.13.707</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0889-2229 |
| ispartof | AIDS research and human retroviruses, 1997-05, Vol.13 (8), p.707-712 |
| issn | 0889-2229 1931-8405 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_15993395 |
| source | Mary Ann Liebert Online Subscription; MEDLINE; Alma/SFX Local Collection |
| subjects | Adenine - analogs & derivatives Adenine - therapeutic use Adenine - toxicity Animals Antibiotics. Antiinfectious agents. Antiparasitic agents Antiviral agents Antiviral Agents - pharmacokinetics Antiviral Agents - therapeutic use Biological and medical sciences CD4-Positive T-Lymphocytes - drug effects Drug Evaluation Lymphocyte Count - drug effects Lymphocyte Subsets - cytology Lymphoid Tissue - pathology Lymphoid Tissue - virology Macaca fascicularis Macaca fascicularis - virology Medical sciences Organophosphonates Organophosphorus Compounds - therapeutic use Organophosphorus Compounds - toxicity Pharmacology. Drug treatments Retroviridae Infections - blood Retroviridae Infections - drug therapy simian immunodeficiency virus Simian Immunodeficiency Virus - drug effects Simian Immunodeficiency Virus - genetics Simian Immunodeficiency Virus - growth & development Tenofovir |
| title | Effects of (R)-9-(2-phosphonylmethoxypropyl)adenine monotherapy on chronic SIV infection in macaques |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T21%3A49%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effects%20of%20(R)-9-(2-phosphonylmethoxypropyl)adenine%20monotherapy%20on%20chronic%20SIV%20infection%20in%20macaques&rft.jtitle=AIDS%20research%20and%20human%20retroviruses&rft.au=TSAI,%20C.-C&rft.date=1997-05-20&rft.volume=13&rft.issue=8&rft.spage=707&rft.epage=712&rft.pages=707-712&rft.issn=0889-2229&rft.eissn=1931-8405&rft.coden=ARHRE7&rft_id=info:doi/10.1089/aid.1997.13.707&rft_dat=%3Cproquest_cross%3E15993395%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=15993395&rft_id=info:pmid/9168239&rfr_iscdi=true |